Clinical Practice Guidelines for Multiple Endocrine Neoplasia Type 1 (MEN1)

Rajesh V. Thakker et al. J Clin Endocrinol Metab 2012; 97: 2990–3011

http://jcem.endojournals.org/content/97/9/2990.full.pdf+html

Guidelines for Diagnosis and Therapy of MEN Type 1 and Type 2

Maria Luisa Brandi et al J Clin Endocrinol Metab 2001; 86(12):5658–5671

http://jcem.endojournals.org/content/86/12/5658.full.pdf+html

Surgical management of pancreatico-duodenal tumors in multiple endocrine neoplasia syndrome type 1

Göran Åkerström, Peter Stålberg, and Per Hellman. Clinics 2012;67(S1):173-178

http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3328819/pdf/cln-67-s1-173.pdf

Biochemically curative surgery for gastrinoma in multiple endocrine neoplasia type 1 patients

Masayuki Imamura, Izumi Komoto, Shuichi Ota, Takuya Hiratsuka, Shinji Kosugi, Ryuichiro Doi, Masaaki Awane, Naoya Inoue World J Gastroenterol 2011 March 14; 17(10): 1343-1353

http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3068271/pdf/WJG-17-1343.pdf

Post-surgical follow-up of primary hyperparathyroidism associated with multiple endocrine neoplasia type 1

Flavia L. Coutinho, Delmar M. Lourenco, Jr., [...], and Sergio P. A. Toledo. CLINICS 2012;67(S1):169-172

http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3328812/pdf/cln-67-s1-169.pdf

Adrenal involvement in MEN1. Analysis of 715 cases from the Groupe d’etude des Tumeurs Endocrines database

B Gatta-Cherifi et al. European Journal of Endocrinology (2012)166 269–279

http://eje-online.org/content/166/2/269.full.pdf+html

Primary hyperparathyroidism in multiple endocrine neoplasia type 1: when to perform surgery?

Francesca Giusti, Francesco Tonelli, and Maria Luisa Brandi. Clinics 2012; 67: 141-44

http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3328829/pdf/cln-67-s1-141.pdf

Diagnosis of Zollinger-Ellison syndrome: Increasingly difficult

Tetsuhide Ito, Guillaume Cadiot, Robert T Jensen. World J Gastroenterol 2012 October 21; 18(39): 5495-5503

http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3482635/pdf/WJG-18-5495.pdf

Variable clinical expression in patients with a germline MEN1 disease gene mutation: clues to a genotype–phenotype correlation

Cornelis J. Lips, Koen M. Dreijerink, Jo W. Hoppener Clinics 2012;67(S1):49-56

http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3328827/pdf/cln-67-s1-49.pdf

Biochemical, bone and renal patterns in hyperparathyroidism associated with multiple endocrine neoplasia type 1

Delmar M. Lourenco Jr.,Flavia L.Coutinho, Rodrigo A. Toledo,Tatiana Denck Goncalves, Fabio L. M.Montenegro, Sergio P. A. Toledo. Clinics 2012;67:99-108

http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3329618/pdf/cln-67-s1-99.pdf

Surgical treatment of pancreatic endocrine tumors in multiple endocrine neoplasia type 1

Marcel Cerqueira Cesar Machado.Clinics 2012;67:145-148

http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3328825/pdf/cln-67-s1-145.pdf

Total parathyroidectomy in a large cohort of cases with hyperparathyroidism associated with multiple endocrine neoplasia type 1: experience from a single academic center

Fabio Luiz de Menezes Montenegro, Delmar Muniz Lourenço, Jr, [...], and Sergio Pereira Almeida Toledo.Clinics 2012;67:131-139

http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3328834/pdf/cln-67-s1-131.pdf

Current Concepts on Gastric Carcinoid Tumors

George C. Nikou and Theodoros P. Angelopoulos. Gastroenterol Res Pract. 2012;2012:287825. doi: 10.1155/2012/287825

http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3534241/pdf/GRP2012-287825.pdf

MENX and MEN4

Natalia S. Pellegata.Clinics 2012;67:13-18

http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3328816/pdf/cln-67-s1-13.pdf

Guidelines for the management of gastroenteropancreatic neuroendocrine (including carcinoid) tumours (NETs)

John K. Ramage et al. Gut 2012;61:6-32 doi:10.1136/gutjnl-2011-300831

http://gut.bmj.com/content/61/1/6.full.pdf+html

Pituitary tumors in patients with MEN1 syndrome

Luis V. Syro, et al. Clinics 2012;67: 43-48

http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3328811/pdf/cln-67-s1-43.pdf

Surgical approach in patients with hyperparathyroidism in multiple endocrine neoplasia type 1: total versus partial parathyroidectomy

Francesco Tonelli, Francesco Giudici, [...], and Maria Luisa Brandi. Clinics 2012;67:155-160

http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3328832/pdf/cln-67-s1-155.pdf

Multiple Endocrine Neoplasia Type 2 and Familial Medullary Thyroid Carcinoma: An Update

Samuel A. Wells, Jr, Furio Pacini, Bruce G. Robinson, and Massimo Santoro. J Clin Endocrinol Metab 2103; 98: 3149–3164

http://jcem.endojournals.org/content/98/8/3149.full.pdf+html

Guidelines for Diagnosis and Therapy of MEN Type 1 and Type 2

Maria Luisa Brandi et al J Clin Endocrinol Metab 2001; 86(12):5658–5671

http://jcem.endojournals.org/content/86/12/5658.full.pdf+html

Modification of multiple endocrine neoplasia 2A phenotype by cell membrane proximity of RET mutations in exon 10

Andreas Machens, Steffen Hauptmann and Henning Dralle. Endocrine-Related Cancer 2009; 17: 171–177

http://erc.endocrinology-journals.org/content/16/1/171.full.pdf+html

Codon-Specific Development of Pheochromocytoma in Multiple Endocrine Neoplasia Type 2

Andreas Machens, Michael Brauckhoff, Hans-Jurgen Holzhausen, Phuong Nguyen Thanh, Hendrik Lehnert, and Henning Dralle. The Journal of Clinical Endocrinology & Metabolism 90(7):3999–4003

http://jcem.endojournals.org/content/90/7/3999.full.pdf+html

Vandetanib for the Treatment of Patients With Locally Advanced or Metastatic Hereditary Medullary Thyroid Cancer

Samuel A. Wells Jr, et al. Journal of Clinical Oncology 2010; 28: 767-72

http://jco.ascopubs.org/content/28/5/767.full.pdf+html

Long-term outcome in 46 gene carriers of hereditary medullary thyroid carcinoma after prophylactic thyroidectomy: impact of individual RET genotype

K Frank-Raue, et al. European Journal of Endocrinology 2006;155: 229–236

http://eje-online.org/content/155/2/229.full.pdf+html

Molecular Basis of Medullary Thyroid Carcinoma: The Role of RET Polymorphisms

Lucieli Ceolin, Débora R. Siqueira, Mírian Romitti, Carla V. Ferreira and Ana Luiza Maia. Int. J. Mol. Sci. 2012.13:221-239

http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3269683/pdf/ijms-13-00221.pdf

Timing and criteria for prophylactic thyroidectomy in asymptomatic RET carriers the role of Ct serum level

Barbara Jarzab, Sylwia Szpak-Ulczok, Jan Wloch, Agnieszka Czarniecka, Jolanta Krajewska. Thyroid Research2013,6 (Suppl 1):S9

http://www.thyroidresearchjournal.com/content/pdf/1756-6614-6-S1-S9.pdf

Medullary Thyroid Cancer: Management Guidelines of the American Thyroid Association. The American Thyroid Association Guidelines Task Force

Richard T. Kloos et al. Thyroid 2009;19 (6): 565-612

http://thyroidguidelines.net/sites/thyroidguidelines.net/files/file/ATA_MTC_Guidelines_2009.pdf

Early Malignant Progression of Hereditary Medullary Thyroid Cancer

Andreas Machens et al. N Engl J Med 2003;349:1517-25

http://www.nejm.org/doi/pdf/10.1056/NEJMoa012915

Modification of multiple endocrine neoplasia 2A phenotype by cell membrane proximity of RET mutations in exon 10

Andreas Machens, Steffen Hauptmann and Henning Dralle. Endocrine-Related Cancer 2009;16:171–177

http://erc.endocrinology-journals.org/content/16/1/171.full.pdf+html

RET oncogene in MEN2, MEN2B, MTC, and other forms of thyroid cancer:molecular genetics and therapeutic advances

Maya B. Lodish, and Constantine A. Stratakis. Expert Rev Anticancer Ther 2008 April ; 8(4): 625–632

http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2670186/pdf/nihms101681.pdf

Age-related neoplastic risk profiles and penetrance estimations in multiple endocrine neoplasia type 2A caused by germ line RET Cys634Trp (TGC>TGG) mutation

Ioana N Milos et al. Endocrine-Related Cancer 2008;15:1035–1041

http://erc.endocrinology-journals.org/content/15/4/1035.full.pdf+html

Genotype-phenotype relationship in multiple endocrine neoplasia type 2. Implications for clinical management

Friedhelm Raue, Karin Frank-Raue. Hormones 2009, 8(1):23-28

http://www.hormones.gr/pdf/MEN2.Genotype-phenotype%20relationship.pdf

Prognostic Factors of Disease-Free Survival after Thyroidectomy in 170 Young Patients with a RET Germline Mutation: A Multicenter Study of the Groupe Français d’Etude des Tumeurs Endocrines

V Rohmer et al. J Clin Endocrinol Metab 2011;96: E509–E518

http://jcem.endojournals.org/content/96/3/E509.full.pdf+html

Kinase inhibitors for advanced medullary thyroid carcinoma

Martin Schlumberger et al. Clinics 2012;67:125-129

http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3328820/pdf/cln-67-s1-125.pdf

Hereditary Medullary Thyroid Cancer: Age-Appropriate Thyroidectomy Improves Disease-Free Survival

Kevin Shepet, BS et al. Ann Surg Oncol 2013 May ; 20(5): 1451–1455

http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3586982/pdf/nihms-417284.pdf

Prophylactic Thyroidectomy in Multiple Endocrine Neoplasia Type 2ª

Michael A. Skinner et al. N Engl J Med 2005;353:1105-13

http://www.nejm.org/doi/pdf/10.1056/NEJMoa043999

The Timing of Total Thyroidectomy in RET Gene Mutation Carriers Could Be Personalized and Safely Planned on the Basis of Serum Calcitonin: 18 Years Experience at One Single Center

Rossella Elisei, et al. J Clin Endocrinol Metab 2012; 97: 426–435

http://jcem.endojournals.org/content/97/2/426.full.pdf+html

TMEM127Screening in a Large Cohort of Patients with Pheochromocytoma and/or Paraganglioma

Nassera Abermil et al. J Clin Endocrinol Metab 2102;97:E805–E809

http://jcem.endojournals.org/content/97/5/E805.full.pdf+htmll

Clinical and molecular genetics of patients with the Carney–Stratakis syndrome and germline mutations of the genes coding for the succinate dehydrogenase subunits SDHB SDHC and SDHD

Barbara Pasini et al. European Journal of Human Genetics 2008; 16, 79-88

http://www.nature.com/ejhg/journal/v16/n1/pdf/5201904a.pdf

Clinical aspects of SDHx-related pheochromocytoma and paraganglioma

Henri J L M Timmers, Anne-Paule Gimenez-Roqueplo, Massimo Mannelli and Karel Pacak. Endocrine-Related Cancer 2009;16: 391–400

http://erc.endocrinology-journals.org/content/16/2/391.full.pdf+html

Genetics and clinical characteristics of hereditary pheochromocytomas and paragangliomas

Jenny Welander, Peter Soderkvist and Oliver Gimm Endocrine-Related Cancer; 2011: 18 R253–R276

http://erc.endocrinology-journals.org/content/18/6/R253.full.pdf+html

Catecholamine metabolomic and secretory phenotypes in phaeochromocytoma

Graeme Eisenhofer et al. Endocrine-Related Cancer; 2011:18: 97-111

http://erc.endocrinology-journals.org/content/18/1/97.full.pdf+html

Comparison of metaiodobenzylguanidine scintigraphy with positron emission tomography in the diagnostic work-up of pheochromocytoma and paraganglioma: a systematic review

Rufini V., Treglia G., Castaldi P., Perotti G., Giordano A

http://www.minervamedica.it/en/journals/nuclear-med-molecular-imaging/article.php?cod=R39Y2013N02A0122

Clinical Risk Factors for Malignancy and Overall Survival in Patients with Pheochromocytomas and Sympathetic Paragangliomas: Primary Tumor Size and Primary Tumor Location as Prognostic Indicators

Montserrat Ayala-Ramirez et al J Clin Endocrinol Metab 2011; 96:717-725

http://jcem.endojournals.org/content/96/3/717.full.pdf+html

Carney Triad: A Syndrome Featuring Paraganglionic, Adrenocortical, and Possibly Other Endocrine Tumors

J. Aidan Carney. J Clin Endocrinol Metab 2009; 94:3656-3662

http://jcem.endojournals.org/content/94/10/3656.full.pdf+html

Genotype and tumor locus determine expression profile of pseudohypoxic pheochromocytomas and paragangliomas

Shankavaram U et al Neoplasia. 2013 Apr;15(4):435-47

http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3612915/pdf/neo1504_0435.pdfl

Genetics and clinical characteristics of hereditary pheochromocytomas and paragangliomas

Jenny Welander, Jenny Welander, Peter Söderkvist and Oliver Gimm. Endocrine-Related Cancer 2011; 18: R253–R276

http://erc.endocrinology-journals.org/content/18/6/R253.full.pdf+html

Age at Diagnosis of Pheochromocytoma Differs According to Catecholamine Phenotype and Tumor Location

Graeme Eisenhofer et al. J Clin Endocrinol Metab 2011; 96: 375–384

http://jcem.endojournals.org/content/96/2/375.full.pdf+html

Current and future therapeutic approaches for metastatic pheochromocytoma and paraganglioma: focus on SDHB tumors

Joey Matro, Alessio Giubellino, Karel Pacak. Horm Metab Res 2013 ; 45: 147–153

http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3577956/pdf/nihms417549.pdf